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lieparm inhibits endothelm-1 production in cultured rat mesangial
cells. The present study was designed to examine whether hepann
inhibits basal or stimulated endothelin-l production by arginine vaso-
pressin (AVP) and platelet-derived growth factor (PDGF) in cultured rat
mesangial cells. In addition, the reversibility of the heparin effect on
mesangial cell endothelin-l production was examined. AVP and PDGF
stimulated endothelin-l secretion in a concentration-dependent manner
in these cells. Heparin (10 to 100 U/mI) exhibited concentration-related
inhibition of AVP- and PDGF-stimulated endothelin-l secretion. Hep-
arm also had weak but significant inhibitory effects on basal endothe-
lin-1 secretion in these cells. The protein kinase (PKC)-activating
phorbor ester, phorbor myristate acetate (PMA), stimulated endothe-
linl secretion and heparin inhibited PMA-stimulated endothelin-1
secretion. In addition, the inhibitory effect of heparin was completely
abolished in PKC-depleted mesangial cells. Mesangial cells which were
exposed to a high concentration (100 U/mI) of heparin for 24 hours were
capable of producing endothelin-1 alter a short lag period of removal of
heparin from the culture medium. These mesangial cells also showed
recovery of responses to AVP and PDGF by secreting a significantly
greater amount of endothelin-l than the non-stimulated level. These
results indicate that heparin potently inhibits mesangial cell endothe-
lin-l production, especially when stimulated by AVP or PDGF. This
inhibitory effect of heparin is probably PKC dependent, and reversible.
Glomerular mesangial cells are directly related to glomerular
function through their contractility and proliferation. These
cells have receptors specific to various vasoactive peptides and
growth factors such as arginine vasopressin (AVP) [1, 2],
endothelin [3, 4] and platelet-derived growth factor (PDGF) [5,
6]. Recent evidence indicates that AVP and PDGF bind to their
specific receptors, and induce the contraction and proliferation
of mesangial cells [1, 7—9].
Endothelin-1 exerts a potent vasoconstrictive effect on a
variety of blood vessels including renal artery [10—12]. This
peptide is also shown to bind to its specific receptors and induce
the contraction and proliferation of glomerular mesangial cells
[3, 13]. Endothelin has been reported to play a role in variety of
diseases that affect the kidney, including severe hypertension
[14-161, acute renal failure [17—19] and cyclosporine nephrotox-
Received for publication April 1, 1993
and in revised form August 3, 1993
Accepted for publication August 8, 1993
© 1994 by the International Society of Nephrology
icity [20, 21]. In fact, we have previously shown that plasma
endothelin-1 levels are significantly increased in hypertensive
patients with impaired renal function and in severe hyperten-
sive rats with renal damage [14, 15]. Furthermore, recent
studies demonstrated constitutive expression of endothelin- 1
transcripts and peptide secretion in cultured rat mesangial cells
[22, 23]. This endothelin-l production by mesangial cells is
found to be stimulated by AVP and PDGF [2, 24, 25]. These
observations have led to the possibility that endothelin-1 may
play a role as a modulator of renal function. On the other hand,
recently we [26] have shown that heparin treatment reduces
vascular endothelial cell production of endothelin- 1 and lowers
blood pressure in spontaneously hypertensive rats (SHR).
Therefore, if heparin inhibits mesangial cell production of
endothelin- 1, heparin treatment may modulate renal function in
certain pathological states, including hypertension and glomer-
ular diseases.
Accordingly, the present study was designed to test the two
hypotheses: (1) that heparin inhibits basal endothelin-1 secre-
tion in cultured rat mesangial cells; and (2) that heparin inhibits
AVP- and PDGF-stimulated endothelin-l secretion in these
cells. In addition, we examined whether this inhibitory effect of
heparin on mesangial cells was reversible.
Methods
Materials
AVP, PDGF, angiotensin II (Ang II), phorbor myristate
acetate (PMA) and heparin were purchased from Sigma Chem-
ical Co. (St. Louis, Missouri, USA). RPM! 1640, trypsin,
Versene® and fetal call serum (FCS) were purchased from
GIBCO Laboratories (Grand Island, New York, USA). Flasks
were purchased from Becton Dickinson and Co. (Oxnard,
California, USA). Endothelin- 1, endothelin-2, endothelin-3,
and big endothelin-1 (porcine, 1-39) were purchased from
Peptide Institute, Inc. (Osaka, Japan). Endothelin-1 antiserum
was purchased from Peninsula Laboratories, Inc. (Belmont,
California, USA). '251-endothelin-1 was purchased from Amer-
sham Japan, Inc. (Tokyo, Japan).
Mesangial cell culture
Glomeruli from Sprague-Dawley rats weighing 50 to 100 g
were isolated by sieving with stainless steel and nylon meshes
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under sterile conditions as previously reported [23]. The iso-
lated glomeruli were then cultured in RPM! 1640 medium
containing 20% FCS and antibiotics. The identity of the mesan-
gial cells was confirmed by the following criteria: (1) morphol-
ogy; (2) typical microfilaments seen by transmission electron
microscopy; (3) survival in a medium containing D-valine
substituted for L-valine, indicating the existence of D-amino
acid oxidase; (4) resistance to puromycin aminonucleoside (10
g!ml) but susceptibility to mitomycin C (10 jg/ml); (5) pres-
ence of receptors specific to Ang II and contraction in response
to Ang II; and (6) absence of immunofluorescence with factor
VIII antibody. The cultures were maintained at 37°C with
atmospheric air and 5% CO2. and subculture was carried out
after treatment with Versene® followed by trypsin. Cells after
three to seven passages were used for this experiment.
Pharmacological treatment
The culture medium was removed and the cell monolayers
were washed twice with serum-free RPMI-1640. Various con-
centrations of AVP (10—6 M, lO M and 108 M) or PDGF (50
ng/ml, S ng/ml and 0.5 ng/ml) were added to the individual wells,
and the cells were incubated at 37°C for 24 and 48 hours. These
concentrations of AVP and PDGF are shown to stimulate
mesangial cell production of endothelin-1 in cultured rat or
human mesangial cells [24, 25]. In separate experiments, vari-
ous concentrations of heparin (100 U/mi, 10 U/nil and 1 U/mI)
were added in the absence or presence of iO M AVP or 5
ng/ml PDGF, and the cells were incubated at 37°C for 24 hours.
In final experiments, we tested whether mesangial cells which
were exposed to a high concentration of heparin (100 U/mi) for
24 hours were capable of producing endothelin-1 after a short
lag period of removal of heparin. The heparin-containing me-
dium was removed and replaced with medium plus 0.5% FCS or
medium plus 0.5% FCS and iO— M AVP or 5 ng/ml PDGF.
Accumulated endothelin-1 levels at 0 to 24 hours, at 24 to 48
hours, and at 48 to 72 hours after the removal of heparin were
measured.
All experiments were performed with 2 ml of RPMI-1640
under quiescent (0.5% FCS) conditions. After the incubation,
the medium was aspirated and centrifuged at 3000 x g for 10
minutes, and the supernatant was collected and stored at —80°C
until radioimmunoassay.
Measurement of endothelin-1 concentration
Immunoreactive (ir)-endothelin-1 was extracted as previ-
ously described [27]. Briefly, 1.5 ml of each sample was diluted
with 4 ml of 4% acetic acid. After centrifugation, the solution
was pumped at the rate of 1 mI/mm through a Sep-Pak C18
cartridge (Millipore Corp., Milford, Massachusetts, USA). M-
ter evaporation of the elute with 86% ethanol in 4% acetic acid
by centrifugal evaporator (Model RD-3 1, Yamato Scientific
Co., Tokyo, Japan), the dry residue was dissolved in the assay
buffer described below. The recovery rate was found by adding
three different quantities of cold endothelin-1 (10, 50 and 100
pg/mi) to serum-free RPM! 1640. Recovery was 69 2%.
The ir-endothelin-1 concentration was assayed using endo-
thelin-1 antiserum and '251-endothelin-l as a tracer. This anti-
body reacts 100% with endothelin-l and cross reacts 7% with
endothelin-2, 7% with endothelin-3 and 35% with big endothe-
lin-1(porcine, 1-39). The antiserum did not cross react with
Table 1. Effects of arginine vasopressin and platelet-derived growth
factor on endothelin- 1 secretion in cultured rat mesangial cells
Endothein-1 level, pg/mi
24hr 48hr
Baseline 5.2 0.7 10.8 1.2
AVP
10 M 10.3 1.0° 20.3 1.5°
M 15.7 + 12ab 29.7 18ab
10—6 M 23.6 19ab 36.2 25b
PDGF
0.5 ng/ml 14.6 2.0 27.5 3.2°
5 ng/ml 23.5 3.1 42.6 4•5ad
50 ng/ml 38.1 5.7° 51.2
Values are mean sD, assays made of 4 cell cultures incubated for
times indicated. Each assay was done in duplicate. AVP, arginine
vasopressin; PDGF, platelet-derived growth factor.
a Significant difference compared with baseline level, P < 0.05
b Significant difference compares with 10_s AVP, P <0.05
Significant difference compared with iO M AVP, P <0.05
< Significant difference compared with 0.5 ng PDGF, P < 0.05
Significant difference compared with 5 ng PDGF, P < 0.05
somatostatin, /3-endorphin, human secretin, Ang II, AVP, or
PDGF.
Radioimmunoassay was performed in an assay buffer of 0.01
M sodium phosphate, p11 7.4, containing 0.05 M NaCl, 0.1%
bovine serum albumin, 0.1% Nonidet P-40 and 0.0 1% NaN3, as
previously described [28]. In brief, rehydrated antiserum (100
ILl) was added to 100 l of the sample or 100 jd of standard
endothelin-l dissolved in the assay buffer and the mixture was
incubated for 24 hours at 4°C. Approximately 15,000 cpm of
'251-endothelin-1 was added to each reaction and incubated for
an additional 24 hours. After this incubation, 100 tl of diluted
normal rabbit serum and 100 d of diluted goat anti-rabbit
immunoglobin 0 were added and the mixture was again incu-
bated for 24 hours. After the third incubation, the precipitate
was collected by centrifugation at 1700 g for 30 minutes. The
supernatant was removed by aspiration and the pellet was
counted for 125! with a gamma counter. The level of detectable
ability of this assay was 0.2 pg/mi with a range of 0.2 to 200
pg/ml. The interassay variation was 13% and the intra-assay
variation was 7%.
AVP, PDGF and heparin did not interfere with the radioim-
munoassay.
Calculations and statistical analysis
The statistical significance of differences in the results were
evaluated by analysis of variance, and P values were calculated
by Scheffe's method [29]. Values are expressed as mean SD.
Results
Effects of AVP and PDGF on mesangial cell endothelin-1
secretion
AVP and PDGF increased ir-endothelin-1 secretion in a
time-dependent fashion. These stimulatory effect were clearly
concentration-dependent (Table 1).
Effects of heparin on basal and stimulated mesangial cell
endothelin-1 secretion
Figure 1 shows effect of heparin on basal mesangial cell
ir-endothelin-1 secretion. Heparin in small dose (1 U/mi) did not
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Fig. 3. Effect of heparin on ir-endothelin-1 secretion from cultured
mesangial cells treated with PDGF. Cells were exposed to different
concentrations of heparin in addition to 5 ng/ml PDGF for 24 hours.
* Significant difference compared with control level (P < 0.05).
+ Significant difference compared with values when PDGF only was









Fig. 2. Effect of heparin on ir-endothelin-1 secretion from cultured
mesangial cells treated with AVP. Cells were exposed to different
concentrations of heparin in addition to l0 M AVP for 24 hours.
* Significant difference compared with control level (P < 0.05).
+ Significant difference compared with values when AVP only was
added (P < 0.05). Each point is the mean of six measurements.
affect basal ir-endothelin-1 secretion (5.2 1.0 pg/mi) com-
pared to control (5.4 0.9 pg/mi). However, in higher doses (10
and 100 U/mi) heparin showed weak but significant inhibitory
effects (10 U/mi, 4.0 0.6 pg/mi; 100 U/mi, 3.4 0.7 pg/mi).
Figure 2 shows effect of heparin on AVP-stimulated ir-
endothelin-1 secretion from cultured mesangial cells. Heparin
in small dose (1 U/mi) did not affect ir-endothelin-1 secretion
(13.0 1.4 pg/mi), whereas 10 and 100 U/mi heparin exhibited
concentration-related inhibition (10 U/mi, 10.5 1.2 pg/mi; 100
U/mi, 7.6 0.9 pg/mi) of AVP-stimulated ir-endothelin-1 secre-
tion (15.5 1.7 pg/mi). However, even in a highest dose (100
U/mi) heparin could not inhibit the secretion to the control level
(7.6 0.9 pg/mi vs. 5.4 0.8 pg/mI).
Figure 3 shows effect of heparin on PDGF-stimulated ir-
endothelin-l secretion from cultured mesangial cells. Heparin
in small dose (1 U/mi) did not affect ir-endothelin- 1 secretion
(21.6 2.5 pg/mi), whereas 10 and 100 U/mi heparin exhibited
concentration-related inhibition (10 U/mi, 17.3 2.3 pg/mi; 100
U/mi, 12.7 1.5 pg/mi) of PDGF-stimulated ir-endothelin-l
secretion (24.3 3.0 pg/mi). However, even in a highest dose
Reversibility of the inhibitory effect of heparin on
endothelin-1 secretion
Next, we tested whether the inhibitory effects of heparin on
mesangial cell ir-endothelin-1 secretion was reversible. At 24
hours after exposure to high concentration (100 U/mi) of
heparin, the heparin-containing medium was removed and
replaced with medium plus 0.5% FCS or medium plus 0.5%
FCS and l0 M AVP or S ng/ml PDGF. Accumulated endo-
thelin-1 levels at 0 to 24 hours, at 24 to 48 hours, and at 48 to 72
hours after the removal of heparin were 3.8 0.5 pg/mi, 4.8
0.6 pg/mi, and 5.8 0.9 pg/mi, respectively (Fig. 5). Mesangial
cells which were previously exposed to heparin were capable of
producing ir-endothein-l after a short lag period of removal of
heparin from the culture medium. These mesangial cells were
also capable of responding to AVP and PDGF and of secreting
significantly greater amounts of endothelin-1 than non-stimu-
lated levels (AVP 0 to 24 hr, 7.0 1.2 pg/mi; AVP 24 to 48 hr,
Endothelin-1 level, pg/mI/24 hr
Control
Heparin, I U/mi
Heparin, 10 U/mI I *
Heparin, 100 U/mI I *
Fig. 1. Effect of heparin on basal ir-endothelin-1 secretion from cul-
tured mesangial cells. Cells were exposed to different concentrations of
heparin for 24 hours. * Significant difference compared with control
level (P < 0.05). Each point is the mean of six measurements.
Endothelin-1 level, pg/mI/24 hr
Endothelin-1 level, pg/mi/24 hr







hepann could not inhibit the secretion to the control level (12.7
0 5 10 15 20 1.5 pg/mi vs. 5.3 0.9 pg/mI).
________
To test the hypothesis that heparin inhibits mesangiai cell
production of endotheiin-l through the inhibition of PKC, the
effect of the PKC-activating phorbor ester, PMA, on ir-endo-
thelin-1 secretion and the effect of heparin on PMA-stimulated
ir-endothelin-l secretion were examined. PMA stimulated ir-
endotheiin- 1 secretion in a concentration-dependent fashion
(control, 5.5 0.9 pg/mi; PMA 10b0 M, 7.8 1.0 pg/mi; PMA
lO M, 10.5 1.1 pg/mi; PMA 108 M, 14.7 1.9 pg/mi; Fig.
4). Hepann clearly inhibited this PMA-stimulated secretion in a
concentration-dependent fashion (heparin 1 U/mi + PMA 108
___________________________
M, 12.9 1.3 pg/mi; heparin 10 U/mi + PMA 108 M, 9.4 0.7
pg/mi; heparin 100 U/mi + PMA 10_8 M, 5.8 0.8 pg/mi; Fig.
4). Actually, in a highest dose (100 U/mI) hepann completely
inhibited PMA-stimulated ir-endothelin-1 secretion.
To confirm the importance of PKC-dependent mechanisms in
the inhibition of endothelin-l by heparin, the effect of heparin
on ir-endothelin- 1 secretion was examined in PKC-depleted
mesangiai cells. PKC-depietion was made by preincubation
with a high dose of PMA (10 M) for 24 hours. The inhibitory
effect of heparin on ir-endotheiin-l secretion was completely
abolished in PKC-depleted cells (Table 2).








heparin, 10 U/mI _____________
PMA, 10°M+
heparin, 100 U/mI
Fig. 4. Effect of the PKC-activating phorbor ester, phorbor myristate
acetate (PMA), on ir-endothelin-l secretion and effect of heparin on
PMA -stimulated ir-endothelin-1 secretion from cultured mesangial
cells. Cells were exposed to different concentrations of PMA for 24
hours. In the same experiment, cells were exposed to different concen-
trations of heparin in addition to 108 M PMA for 24 hours. * Significant
difference compared with control level (P < 0.05). + Significant
difference compared with values when 10_s PMA only was added (P




(—) 5.5 0.9 3.5 0.6 <0.05(+) 3.4 0.7 3.2 0.8 NS
9.2 1.2 pg/mi; AVP 48 to 72 hr, 13.6 1.2 pg/nil) (PDGF 0 to
24 hr, 7.0 1.2 pg/mi; PDGF 24 to 48 hr, 12.6 1.6 pg/mi,
PDGF 48 to 72 hr, 19.0 2.4 pg/mi; Fig. 5). Furthermore, the
above-mentioned heparin-containing medium did not contain
detached cells. The inhibitory effects of hepann on mesangial
cell endothelm-l production thus appear to be reversible and
not simply a function of killing mesangial cells.
Discussion
In the present study, we have confirmed the previous reports
that AVP as well as PDGF stimulates a vasoconstrictive and
growth-promoting peptide, endothelin- 1, in cultured rat mesan-
gial cells [2, 24, 25] and we have presented data for the first time
that heparin inhibits AVP- and PDGF-stimulated endothelin-1
secretion in these cells. We also have shown that heparin was
weak but significant inhibitory effects on basal endothelin-1
Accumulated endothelin-1 level, pg/ml/24 hr
0 5 10 15 20 25
Control
AVP, 10-7M I *
PDGF,5ng/m/ rArA_l*
B 24 hr—48 hr after the removal of heparin
Accumulated endothelin-1 level, pg/ml/24 hr
0 5 10 15 20 25
Control
AVP, 107M —I *
PDGF,5ng/ml
C 48 hr—72 hr after the removal of heparin
Accumulated endothelin-1 level, pg/ml/24 hr





Fig. S. Reversibility of the heparin effect on mesangial cell endothe-
un-I production. Heparin-containing medium was replaced with me-
dium alone or medium plus i0M AVP or 5 ng/ml PDGF. Accumulated
endothelin-1 levels at 0 to 24 hours, at 24 to 48 hours, and at 48 to 72
hours after the removal of heparin were shown. * Significant difference
compared with control level (with 0.5% FCS only) (P < 0.05). Each
point is the mean of six measurements.
secretion in cultured rat mesangial cells. The present results are
in agreement with our recent report [26] that heparin inhibits
endothelin-1 secretion in cultured rat aortic endothelial cells.
Next, we showed that the PKC-activating phorbor ester,
PMA, stimulated endothelin-1 secretion and heparin clearly
inhibited PMA-stimulated endothelin-l secretion. Actually, a
high dose (100 U/mi) of heparin completely suppressed PMA-
stimulated endothelin- 1 secretion. However, this suppressive
effect of heparin was abolished in PKC-depleted mesangial
cells. Therefore, our findings suggest that heparin suppresses
mesangial cell production of endothelin-1 probably through a
mechanism of inhibition of PKC. Although PKC-depletion
prevented the heparin-induced fall in endotheiin-1 production,
the baseline levels with PKC-depletion were similar to the
heparin-induced fall. One possible explanation is that the basal
endothelin-l production is also PKC-dependent and heparin
inhibits the basal endothelin-l production as well as AVP- and
PDGF-stimulated production most likely through a common
mechanism of inhibition of PKC. We speculate that even in
Endothelin-1 level, pg/ml/24 hr
0 5 10 15 20






Table 2. Effect of heparin on endothelin-l Secretion in cultured rat




Values are mean SD, and assays were made of 4 cell cultures
incubated for 24 hours. Each assay was done in duplicate. To deplete
PKC, the cells were preincubated with l0 M PMA for 24 hours.
Abbreviations are: PKC. protein kinase C; NS, not significant; PMA
phorbor myristate acetate.
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basal conditions mesangial cell production of endothelin- 1 may
be stimulated by endogenously produced substances, such as
PDGF, through the activation of PKC. Actually, previous
evidence indicates that mesangial cells themselves produce a
PDGF-like molecule [9] and PDGF induces its own messenger
RNA in mesangial cells [30].
Hepann has many pharmacologic effects other than antico-
agulation. Previous studies indicate that heparin treatment
reduces blood pressure and improves renal function in several
experimental hypertensive models [3 1—34]. In addition, Castel-
lot et al [35] have demonstrated that heparin inhibits mesangial
cell proliferation. In the present study, we showed that heparin
inhibits basal and AVP- or PDGF-stimulated mesangial cell
production of endothelin-1. Taken together, these findings
indicate that endothelin- 1 has vasoconstrictive effect on renal
vasculature and some mitogenic activities for glomerular me-
sangial cells. Thus heparin treatment by its inhibitory effects on
production of endothelin-1 in vascular endothelial and mesan-
gial cells, as well as by its anticoagulation and antimitogenic
action, may help to attenuate hypertension and glomerular
dysfunction.
Finally, we showed that mesangial cells which were exposed
to a high concentration of heparin for 24 hours were capable of
secreting endothelin-l. These mesangial cells also were capable
of responding to AVP and PDGF and of secreting greater
amount of endothelin-1 than non-stimulated level. These results
suggest that the inhibitory effect of heparin on mesangial cell
production of endothelin- 1 is reversible and not simply a
function of killing mesangial cells. Actually, heparin-containing
medium in our experiment did not contain detached cells.
Overall, our data indicate that heparin inhibits mesangial cell
endothelin-1 secretion probably through the inhibition of PKC
and this effect is reversible. Therefore, heparin treatment may
modulate glomerular hemodynamics in part through the inhibi-
tion of mesangial endothelin-1 production, especially when
endogenous endothelin-1 production is enhanced by AVP or
PDGF. If so, this action may be added to the anticoagulation
and antimitogenic action [35] as yet another effect of heparin of
benefit in certain pathological states. However, it remains to be
clarified whether heparin has a role in modulating endothelin- 1
production in glomerular mesangial cells in vivo, since high
concentrations of heparin are required to inhibit the AVP or
PDGF effect on endothelin-1 production. In addition, further
investigation will be necessary to elucidate the exact cellular
mechanism by which heparin inhibits mesangial cell endothe-
lin-l production.
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